Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

BL-7040 · EN-101

Oligonucleotide · developed by BioLineRx

Phase 2 Most advanced trial (none active)
BLRX Developer
1 Registered trials

What is BL-7040?

BL-7040 is a synthetic oligonucleotide with dual activity on both the nervous and immune systems, studied for the treatment of inflammatory bowel disease and ulcerative colitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
EN-101
Drug type
Oligonucleotide
Therapy area
Gastroenterology
Developer
BioLineRx, Ltd. (BLRX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
4TT3V55XYT

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01506362 Phase 2 Ulcerative Colitis Completed BLRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ulcerative Colitis

More from BioLineRx

BL-1020 Phase 2 BL-1021 Phase 1 BL-7010 Phase 1/2 CYP-1020 Phase 2/3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BLRX page.

Follow BLRX, the company behind BL-7040

See BLRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BLRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.